alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 333.110 First aid antibiotic active ingredients. The product consists of any of the following active ingredients within the specified concentration established for each ingredient and in the specified dosage form: ( a ) Bacitracin ointment containing, in each gram, 500 units of bacitracin in a suitable ointment base.
( b ) Bacitracin zinc ointment containing, in each gram, 500 units of bacitracin zinc in a suitable ointment base.
( c ) Chlortetracycline hydrochloride ointment containing, in each gram, 30 milligrams of chlortetracycline hydrochloride in a suitable ointment base.
( d ) Neomycin sulfate ointment containing, in each gram, 3.5 milligrams of neomycin in a suitable water soluble or oleaginous ointment base.
( e ) Neomycin sulfate cream containing, in each gram, 3.5 milligrams of neomycin in a suitable cream base.
( f ) Tetracycline hydrochloride ointment containing, in each gram, 30 milligrams of tetracycline hydrochloride in a suitable ointment base.
[52 FR 47322, Dec. 11, 1987, as amended at 53 FR 18838, May 25, 1988; 64 FR 403, Jan. 5, 1999]
---

---

Exhibit
  13.1


Section 906 Certification
  CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  PURSUANT TO 18 U.S.C. SECTION 1350

In
  connection with the accompanying Annual Report on Form 20-F of NUR Macroprinters
  Ltd. for the year ended December 31, 2003, the undersigned officer, being the
  Chief Executive Officer of NUR Macroprinters Ltd., hereby certifies pursuant
  to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
  Act of 2002, that:

| | (1) | such
      Annual Report on Form 20-F for the year ended December 31, 2003 fully complies
      with the requirements of Section 13(a) or 15(d) of the Securities Exchange
      Act of 1934; and                                          
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                                                                                            
| | (2) | the
      information contained in such Annual Report on Form 20-F for the year ended
      December 31, 2003 fairly presents, in all material respects, the financial
      condition and results of operations of NUR Macroprinters Ltd..

This
  written statement is being furnished to the Securities and Exchange Commission
  as an exhibit to such Form 20-F.

|March
      30, 2004 |                                       
|-------------------- | --------------------------------------
|                     |                                       
|Date                 |                                       
|                     |                                       
|                     | /s/ DavidAmir                         
|                     |                                       
|                     | DavidAmirChief
      Executive Officer

---

---
Opinion issued August 12, 2014.

In The

Court of Appeals 

For The 

First District of Texas 

————————————

NO. 01-14-00008-CV

———————————

EZINNE UBANI, Appellant

V.

MAZEN JUMAA, Appellee

On Appeal from the 270th District Court

Harris County, Texas

Trial Court Case No. 2012-43470

MEMORANDUM OPINION

Appellant, Ezinne Ubani, has neither established indigence nor paid, or 

made arrangements to pay, the fee for preparing the clerk’s record. See TEX. R.
2

APP. P. 20.1, 37.3(b). After being notified that this appeal was subject to dismissal, 

appellant did not adequately respond. See TEX. R. APP. P. 42.3(b).

We dismiss the appeal for want of prosecution. We dismiss any pending 

motions as moot.

PER CURIAM

Panel consists of Justices Sharp, Keyes, and Huddle.
Michigan Supreme Court

Lansing, Michigan

Bridget M. McCormack, Chief Justice

Brian K. Zahra

David F. Viviano

Richard H. Bernstein

Elizabeth T. Clement

Megan K. Cavanagh

Elizabeth M. Welch,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 April 30, 2021

a0427

Order 

Clerk

April 30, 2021

162208

PEOPLE OF THE STATE OF MICHIGAN, 

Plaintiff-Appellee,

v SC: 162208

COA: 338877

Berrien CC: 2015-005091-FH

JOHN ANTONYA MOSS,

Defendant-Appellant. 

_________________________________________/

On order of the Court, the application for leave to appeal the September 10, 2020 

judgment of the Court of Appeals is considered. We direct the Clerk to schedule oral 

argument on the application. MCR 7.305(H)(1). 

The appellant shall file a supplemental brief addressing whether the Court of 

Appeals erred in concluding on remand that the defendant and the complainant are 

effectively related by blood for purposes of MCL 750.520d(1)(d), such that there was an 

adequate factual basis for the defendant’s no-contest plea.

The appellant’s brief shall be filed by August 30, 2021, with no extensions except 

upon a showing of good cause. In the brief, citations to the record must provide the 

appendix page numbers as required by MCR 7.312(B)(1). The appellee shall file a 

supplemental brief within 21 days of being served with the appellant’s brief. A reply, if 

any, must be filed by the appellant within 14 days of being served with the appellee’s 

brief. The parties should not submit mere restatements of their application papers.

The Prosecuting Attorneys Association of Michigan and the Criminal Defense 

Attorneys of Michigan are invited to file briefs amicus curiae. Other persons or groups 

interested in the determination of the issue presented in this case may move the Court for 

permission to file briefs amicus curiae.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule  contains summary  financial  information  extracted from the
Balance  Sheet and Statement of Operations as of and for the 13 weeks endeed May
1,  1999  and is  qualified  in its  entirety  by  reference  to such  financial
statements as included in the Company's Quarterly Report on Form 10-Q.
 </LEGEND>
<CIK>                                          0000813775
<NAME>                                         Factory 2-U Stores, Inc.
<MULTIPLIER>                                   1,000


<S>                                            <C>
<PERIOD-TYPE>                                  3-MOS
<FISCAL-YEAR-END>                              JAN-29-2000
<PERIOD-START>                                 JAN-31-1999
<PERIOD-END>                                   MAY-1-1999
<CASH>                                         4,562
<SECURITIES>                                   0
<RECEIVABLES>                                  0
<ALLOWANCES>                                   0
<INVENTORY>                                    36,191
<CURRENT-ASSETS>                               45,884
<PP&E>                                         33,553
<DEPRECIATION>                                 13,600
<TOTAL-ASSETS>                                 99,498
<CURRENT-LIABILITIES>                          56,833
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       121
<OTHER-SE>                                     27,732
<TOTAL-LIABILITY-AND-EQUITY>                   99,498
<SALES>                                        85,099
<TOTAL-REVENUES>                               85,099
<CGS>                                          56,108
<TOTAL-COSTS>                                  56,108
<OTHER-EXPENSES>                               27,886
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             539
<INCOME-PRETAX>                                566
<INCOME-TAX>                                   232
<INCOME-CONTINUING>                            334
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   334
<EPS-BASIC>                                  0.03
<EPS-DILUTED>                                  0.03



</TABLE>
<PAGE>
                                                                    EXHIBIT 99.1
 
                         ANNUAL SERVICER'S CERTIFICATE
                            RETAILERS NATIONAL BANK
                     DAYTON HUDSON CREDIT CARD MASTER TRUST
 
    The undersigned, a duly authorized representative of Retailers National
Bank, as Servicer ("RNB"), pursuant to the Pooling and Servicing Agreement dated
as of September 13, 1995, as supplemented by the Series 1995-1 Supplement and
the Series 1996-1 Supplement (as may be amended and supplemented from time to
time, the "Agreement"), among Dayton Hudson Receivables Corporation, as
Transferor, RNB as Servicer, and Norwest Bank Minnesota, National Association,
as Trustee, does hereby certify that:
 
    1.  RNB is, as of the date hereof, the Servicer under the Agreement.
       Capitalized terms used in this Certificate have their respective meanings
       as set forth in the Agreement.
 
    2.  The undersigned is a Servicing Officer who is duly authorized pursuant
       to the Agreement to execute and deliver this certificate to the Trustee.
 
    3.  A review of the activities of the Servicer during the fiscal year ended
       January 4, 1997, and of its performance under the Agreement was conducted
       under my supervision.
 
    4.  Based on such review, the Servicer has, to the best of my knowledge,
       performed in all material respects its obligations under the Agreement
       throughout such year and no default in the performance of such
       obligations has occurred or is continuing except as set forth in
       paragraph 5 below.
 
    5.  The following is a description of each default in the performance of the
       Servicer's obligations under the provisions of the Agreement known to me
       to have been made by the Servicer during the fiscal year ended January 4,
       1997 which sets forth in detail (i) the nature of each default, (ii) the
       action taken by the Servicer, if any, to remedy each such default and
       (iii) the current status of each such default: None.
 
    IN WITNESS WHEREOF, the undersigned has duly executed this Certificate as of
the 20th day of March, 1997.
 
                                RETAILERS NATIONAL BANK,
                                AS SERVICER,
 
                                By:  /s/ THOMAS A. SWANSON
                                     -----------------------------------------
                                     Name: Thomas A. Swanson
                                     Title: VICE PRESIDENT & CASHIER
 
                                       7
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 23-6913

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

ALVIN BERNARD TRUESDALE,

Defendant - Appellant.

Appeal from the United States District Court for the Western District of North Carolina, at 

Charlotte. Robert J. Conrad, Jr., District Judge. (3:92-cr-00034-RJC-1)

Submitted: June 25, 2024 Decided: June 27, 2024

Before RICHARDSON and QUATTLEBAUM, Circuit Judges, and TRAXLER, Senior 

Circuit Judge.

Affirmed by unpublished per curiam opinion.

Alvin Bernard Truesdale, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

USCA4 Appeal: 23-6913 Doc: 9 Filed: 06/27/2024 Pg: 1 of 2
2

PER CURIAM:

Alvin Bernard Truesdale appeals the district court’s order granting his motion to 

reduce his sentence to time served and denying several pro se motions. We have reviewed 

the record and find no reversible error. Accordingly, we affirm the district court’s order. 

United States v. Truesdale, No. 3:92-cr-00034-RJC-1 (W.D.N.C. Aug. 30, 2023). We 

dispense with oral argument because the facts and legal contentions are adequately 

presented in the materials before this court and argument would not aid the decisional 

process.

AFFIRMED

USCA4 Appeal: 23-6913 Doc: 9 Filed: 06/27/2024 Pg: 2 of 2
##### 



Exhibit 32(b) Certification of Chief Financial Officer Pursuant to 18 U.S.C. § 1350
(Section 906 of the Sarbanes-Oxley Act of 2002) Pursuant to 18 U.S.C. § 1350, the undersigned officer of Republic Bancorp Inc.
(the Company) hereby certifies, to such officers knowledge, that the
Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2004
(the Report) fully complies with the requirements of Section 13(a) or 15(d),
as applicable, of the Securities Exchange Act of 1934 and that the information
contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company. Dated: August 6, 2004
    /s/ Thomas F. MenacherName:
    Thomas F. MenacherTitle:
    Executive Vice President, Treasurer
and Chief Financial Officer The foregoing certification (i) accompanies the filing and is being furnished
solely pursuant to 18 U.S.C. § 1350, (ii) will not be deemed filed for
purposes of Section 18 of the Exchange Act of 1934, or otherwise subject to the
liability of that section, and (iii) will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933 or the Exchange Act,
except to the extent that the registrant specifically incorporates it by
reference. A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written
statement required by Section 906, has been provided to Republic Bancorp Inc.
and will be retained by Republic Bancorp Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.
§ 520.1696c Penicillin V tablets. ( a ) *Specifications.* Each tablet contains penicillin V potassium equivalent to 125 milligrams (200,000 units) or 250 milligrams (400,000 units) of penicillin V.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* 10 to 15 milligrams per pound of body weight every 6 to 8 hours.
( 2 ) *Indications for use.* Treatment of respiratory, urogenital, skin and soft tissue infections and septicemia caused by pathogens susceptible to penicillin V potassium.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37327, Aug. 18, 1992, as amended at 59 FR 58775, Nov. 15, 1994; 78 FR 28826, May 20, 2014; 84 FR 39183, Aug. 9, 2019. Redesignated at 85 FR 18119, Apr. 1, 2020; 88 FR 27699, May 3, 2023]
Exhibit 14.1




Consent of Independent Registered Public Accounting Firm




We consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-102288 and 333-92491) pertaining to the Employee Stock Option plans of Ellomay Capital Ltd. (“the Company”) and Form F-3 (File Nos. 333-144171, 333-115826, 333-114428, 333-47842 and 333-92493) of the Company and in the related Prospectuses of our report dated March 10, 2010, with respect to the consolidated financial statements of Ellomay Capital Ltd. and its subsidiaries included in this Annual Report on Form 20-F/A for the year ended December 31, 2009.


/s/ Kost Forer Gabbay & KasiererTel Aviv, Israel
KOST FORER GABBAY & KASIERERNovember 12, 2010
A Member of Ernst & Young Global
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1613 Potassium bicarbonate. ( a ) Potassium bicarbonate (KHCO3, CAS Reg. No. 298-14-6) is made by the following processes: ( 1 ) By treating a solution of potassium hydroxide with carbon dioxide;
( 2 ) By treating a solution of potassium carbonate with carbon dioxide.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 239, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a formulation aid as defined in § 170.3(o)(14) of this chapter; nutrient supplement as defined in § 170.3(o)(20) of this chapter; pH control agent as defined in § 170.3(o)(23) of this chapter; and processing aid as defined in § 170.3(o)(24) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52442, Nov. 18, 1983]
§ 507.73 Requirements applicable to an informal hearing. If you request an informal hearing, and FDA grants the request: ( a ) The hearing will be held within 15 calendar days after the date the appeal is filed or, if applicable, within a timeframe agreed upon in writing by you and FDA.
( b ) The presiding officer may require that a hearing conducted under this subpart be completed within 1 calendar day, as appropriate.
( c ) FDA must conduct the hearing in accordance with part 16 of this chapter, except that: ( 1 ) The order withdrawing an exemption under §§ 507.62 and 507.65, rather than the notice under § 16.22(a) of this chapter, provides notice of opportunity for a hearing under this section and is part of the administrative record of the regulatory hearing under § 16.80(a) of this chapter.
( 2 ) A request for a hearing under this subpart must be addressed to the FDA Division Director (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine) as provided in the order withdrawing an exemption.
( 3 ) Section 507.75, rather than § 16.42(a) of this chapter, describes the FDA employees who preside at hearings under this subpart.
( 4 ) Section 16.60(e) and (f) of this chapter does not apply to a hearing under this subpart. The presiding officer must prepare a written report of the hearing. All written material presented at the hearing will be attached to the report. The presiding officer must include as part of the report of the hearing a finding on the credibility of witnesses (other than expert witnesses) whenever credibility is a material issue, and must include a proposed decision, with a statement of reasons. The hearing participant may review and comment on the presiding officer's report within 2 calendar days of issuance of the report. The presiding officer will then issue the final decision.
( 5 ) Section 16.80(a)(4) of this chapter does not apply to a regulatory hearing under this subpart. The presiding officer's report of the hearing and any comments on the report by the hearing participant under paragraph (c)(4) of this section are part of the administrative record.
( 6 ) No party shall have the right, under § 16.119 of this chapter to petition the Commissioner of Food and Drugs for reconsideration or a stay of the presiding officer's final decision.
( 7 ) If FDA grants a request for an informal hearing on an appeal of an order withdrawing an exemption, the hearing must be conducted as a regulatory hearing under a regulation in accordance with part 16 of this chapter, except that § 16.95(b) does not apply to a hearing under this subpart. With respect to a regulatory hearing under this subpart, the administrative record of the hearing specified in §§ 16.80(a)(1) through (3), and (a)(5), of this chapter, and 507.73(c)(5) constitutes the exclusive record for the presiding officer's final decision. For purposes of judicial review under § 10.45 of this chapter, the record of the administrative proceeding consists of the record of the hearing and the presiding officer's final decision.
[80 FR 56337, Sept. 17, 2015, as amended at 85 FR 16554, Mar. 24, 2020]
GLOBAL INTELLICOM, INC. AND SUBSIDIARIES

                                   EXHIBIT 11

                     COMPUTATION OF INCOME PER COMMON SHARE


<TABLE>
<CAPTION>
                                                                              YEARS ENDED DECEMBER 31,
                                                                    ------------------------------------------
                                                                         1997           1996            1995
                                                                    -------------   -----------     ----------
<S>                                                                  <C>             <C>             <C>       
INCOME PER COMMON SHARE

INCOME:

   Income (loss) from continuing operations                          $  (2,302,808)  $  (706,493)    $  203,332

   Less:  Dividends                                                        188,673          -              -

   Less:  Cumulative undeclared dividend
     on Series 3 Convertible Preferred Stock                                61,250        61,250           -
                                                                     -------------   -----------     ----------

   Adjusted income (loss) from continuing operations                 $  (2,552,731)  $  (767,743)    $  203,332
                                                                     =============   ===========     ==========

   Discontinued operations                                           $  (7,133,152)  $  (378,895)    $   66,851
                                                                     =============   ===========     ==========


SHARES:

   Weighted average number of common
     shares outstanding                                                  7,481,307     3,527,053      2,927,170
                                                                         =========     =========      =========

BASIC INCOME (LOSS) PER COMMON SHARE:
   Income (loss) from continuing operations                          $        (.34)  $      (.22)    $      .07
   Discontinued operations                                                    (.95)         (.11)           .02
                                                                     -------------   -----------     ----------
                                                                    $        (1.29)  $      (.33)    $      .09
                                                                     =============   ===========     ==========
</TABLE>


                                      F-47
Exhibit 23.1

# Consent of Independent
Auditors

We consent to the incorporation by
reference in the Registration Statements (Form S-8 No. 333- 92491 and No. 333-102288)
filed with the Securities and Exchange Commission pertaining to the 1995 Israel stock
option Plan, 1997 Stock Option Plan and 1998 Non-Employee Director Share Option Plan and
pertaining to the 2000 Stock Option Plan of Nur Macroprinters, of our report dated March
11, 2003, with respect to the consolidated financial statements and schedules of Nur
Macroprinters included in this Annual Report (Form 20-F) for the year ended December 31,
2002.

Tel-Aviv, Israel May14,
2003

| | Yours truly,
/S/ Kost Forer & Gabbay
KOST FORER & GABBAY
A Member of Ernst & Young Global
| | -----------------------------------------------------------------------------------------



---

---